Aspirin or Ticagrelor in Staphylococcus aureus Infective Endocarditis: Where Do We Stand?
13 октября 2021 года
09:51
Aspirin or Ticagrelor in Staphylococcus aureus Infective Endocarditis: Where Do We Stand?
Текст новости:
Title: Aspirin or Ticagrelor in Staphylococcus aureus Infective Endocarditis: Where Do We Stand?
Author, co-author: Leeten, Kirsten; Jacques, Nicolas; LANCELLOTTI, Patrizio; Oury, Cécile
Abstract: Infective endocarditis is a challenging disease with a high mortality and morbidity rate. Antibiotic prophylaxis is currently recommended in high-risk infective endocarditis patients. However, the use of antibiotics faces the challenge of a low efficacy and contributes further to the emerging infection rate by antibiotic-resistant strains, emphasizing the need for new therapeutic strategies. Platelets are essential in the initial phase of infective endocarditis, acting as first-line immune responders. During the first phase of disease, bacteria can interact with platelets and counteract platelet antimicrobial activities. Mechanistic in vitro and animal studies on the effect of aspirin on bacteria-platelet interactions and the prevention of vegetation development showed promising results. However, data from clinical studies on the outcome of infective endocarditis patients who were receiving medically indicated aspirin therapy remain controversial. Therefore, the benefit of antiplatelet agents in infective endocarditis prevention has been questioned. Besides aspirin, it has been discovered that the platelet P2Y12 receptor antagonist ticagrelor has antibacterial properties in addition to its potent antiplatelet activity. Furthermore, a recent study in mice and a case report remarkably indicated the ability of this drug to eradicate Staphylococcus aureus bacteremia. This review will focus on current knowledge on antibacterial activity of ticagrelor, compared to aspirin, pointing out main unanswered questions. The goal is to provide food for thought as to whether a prior ticagrelor therapy might be beneficial for the prevention of infective endocarditis.


Текст со страницы (автоматическое получение):
Aspirin or Ticagrelor in Staphylococcus aureus Infective Endocarditis: Where Do We Stand?
Language :
Publication date :
Abstract :
[en] Infective endocarditis is a challenging disease with a high mortality and morbidity rate. Antibiotic prophylaxis is currently recommended in high-risk infective endocarditis patients. However, the use of antibiotics faces the challenge of a low efficacy and contributes further to the emerging infection rate by antibiotic-resistant strains, emphasizing the need for new therapeutic strategies. Platelets are essential in the initial phase of infective endocarditis, acting as first-line immune responders. During the first phase of disease, bacteria can interact with platelets and counteract platelet antimicrobial activities. Mechanistic in vitro and animal studies on the effect of aspirin on bacteria-platelet interactions and the prevention of vegetation development showed promising results. However, data from clinical studies on the outcome of infective endocarditis patients who were receiving medically indicated aspirin therapy remain controversial. Therefore, the benefit of antiplatelet agents in infective endocarditis prevention has been questioned. Besides aspirin, it has been discovered that the platelet P2Y12 receptor antagonist ticagrelor has antibacterial properties in addition to its potent antiplatelet activity. Furthermore, a recent study in mice and a case report remarkably indicated the ability of this drug to eradicate Staphylococcus aureus bacteremia. This review will focus on current knowledge on antibacterial activity of ticagrelor, compared to aspirin, pointing out main unanswered questions. The goal is to provide food for thought as to whether a prior ticagrelor therapy might be beneficial for the prevention of infective endocarditis.
Research centres :
Laboratory of Cardiology, Department of Cardiology, GIGA Institute, University of Liège Hospital, Liège, Belgium ; Gruppo Villa Maria Care and Research, Maria Cecilia Hospital, Cotignola, and Anthea Hospital, Bari, Italy
Funders :
Автоматическая система мониторинга и отбора информации
Источник
Другие материалы рубрики
★★★  13 октября 2021 года
09:52
Concept and prototype V4F for classification
★★★★★  13 октября 2021 года
07:07
Competence profile for the occupational clinician
★★★★★  12 октября 2021 года
20:06
Logiciel Vibra4Fake 2020
★★★★★  12 октября 2021 года
18:23
Networking during your PhD, suggestion and examples
★★★★★  12 октября 2021 года
14:38
L’ammoniac liquide : un carburant vert pour le secteur du transport ?